查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1322219

肿瘤血液学分子检测市场 - 全球行业分析、规模、份额、增长、趋势和预测，2023-2031 年

Onco-hematology Molecular Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 179 Pages | 商品交期: 2-10个工作天内

价格

肿瘤血液学分子检测市场 - 报告范围

TMR 关于全球肿瘤血液学分子检测市场的报告研究了过去以及当前的增长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球 Onco 的收入-2017-2031年期间的血液学分子检测市场，考虑2023年为基准年，2031年为预测年。该报告还提供了2023年至2031年全球肿瘤血液学分子检测市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领袖和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解肿瘤血液学分子检测市场。

该报告深入研究了全球肿瘤血液学分子检测市场的竞争格局。全球肿瘤血液学分子检测市场的主要参与者已经确定，并且每一位参与者都已根据各种属性进行了分析。公司概述、财务状况、最新发展和 SWOT 是本报告中介绍的全球肿瘤血液学分子检测市场参与者的属性。

目录

第一章：前言

第 2 章：假设和研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年全球市场分析与预测

第 5 章：关键见解

  • 市场概况
  • 主要产品/品牌分析
  • 管道分析
  • COVID-19 大流行对行业的影响

第 6 章：全球市场分析与预测：按血癌类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按血癌类型，2017-2031
    • 慢性粒细胞白血病
      • 真性红细胞增多症
      • 原发性血小板增多症
      • 骨髓纤维化
    • 骨髓增生性肿瘤
    • 急性髓系白血病
    • 急性淋巴细胞白血病
  • 市场吸引力分析：按血癌类型

第 7 章：全球市场分析与预测：按血癌生物标誌物分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按血癌生物标誌物分类，2017-2031
    • BCR-ABL1 MBCR
    • 贾克2
    • 卡拉尔
    • 多普勒
    • PML-RARA
    • NPM1
    • RUNX1-RUNX1T1
    • CBFB-MYH11
    • BCR-ABL1 mbcr
  • 市场吸引力分析：按血癌生物标誌物

第 8 章：全球市场分析与预测：按技术分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按技术分类，2017-2031
    • 定量PCR
    • 聚合酶炼式反应
    • 下一代测序
    • 其他的
  • 市场吸引力分析：按技术分类

第 9 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2017-2031
    • 国家参考实验室/专业实验室
    • 大学医院/肿瘤中心
    • 社区医院/IDN（地区/国家
  • 市场吸引力分析：按最终用户

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美
    • 欧洲
    • 亚太地区
    • 拉美
    • 中东和非洲
  • 市场吸引力分析：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（按公司层级和规模）
  • 市场份额分析：按公司划分，2022 年
  • 公司简介
    • Asuragen, Inc.
    • Bio-Rad Laboratories, Inc.
    • ICON plc
    • Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
    • Invivoscribe, Inc.
    • QIAGEN NV
    • Thermo Fisher Scientific, Inc.
    • Cepheid
    • Illumina, Inc.
Product Code: TMRGL85642

Onco-hematology Molecular Testing Market - Scope of Report

TMR's report on the global Onco-hematology Molecular Testing Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Onco-hematology Molecular Testing Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Onco-hematology Molecular Testing Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Onco-hematology Molecular Testing Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Onco-hematology Molecular Testing Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Onco-hematology Molecular Testing Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Onco-hematology Molecular Testing Market.

The report delves into the competitive landscape of the global Onco-hematology Molecular Testing Market. Key players operating in the global Onco-hematology Molecular Testing Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Onco-hematology Molecular Testing Market profiled in this report.

Key Questions Answered in Global Onco-hematology Molecular Testing Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Onco-hematology Molecular Testing Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Onco-hematology Molecular Testing Market - Research Objectives and Research Approach

The comprehensive report on the global Onco-hematology Molecular Testing Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Onco-hematology Molecular Testing Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Onco-hematology Molecular Testing .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Onco-hematology Molecular Testing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Onco-hematology Molecular Testing Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Overview of Onco-hematology Molecular Testing Market
  • 5.2. Key Product/ Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 6.3.1. Chronic Myeloid Leukemia
      • 6.3.1.1. Polycythemia Vera
      • 6.3.1.2. Essential Thrombocythaemia
      • 6.3.1.3. Myelofibrosis
    • 6.3.2. Myeloproliferative Neoplasms
    • 6.3.3. Acute Myeloid Leukemia
    • 6.3.4. Acute Lymphoblastic Leukemia
  • 6.4. Market Attractiveness Analysis, by Blood Cancer Type

7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 7.3.1. BCR-ABL1 MBCR
    • 7.3.2. JAK2
    • 7.3.3. CALR
    • 7.3.4. MPL
    • 7.3.5. PML-RARA
    • 7.3.6. NPM1
    • 7.3.7. RUNX1-RUNX1T1
    • 7.3.8. CBFB-MYH11
    • 7.3.9. BCR-ABL1 mbcr
  • 7.4. Market Attractiveness Analysis, by Blood Cancer Biomarker

8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Technology, 2017-2031
    • 8.3.1. qPCR
    • 8.3.2. dPCR
    • 8.3.3. Next-Generation Sequencing
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by Technology

9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. National Reference Lab/Specialty Lab
    • 9.3.2. University Hospital/Oncology Center
    • 9.3.3. Community Hospital/IDN (Regional/National
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Onco-hematology Molecular Testing Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 11.2.1. Chronic Myeloid Leukemia
      • 11.2.1.1. Polycythemia Vera
      • 11.2.1.2. Essential Thrombocythaemia
      • 11.2.1.3. Myelofibrosis
    • 11.2.2. Myeloproliferative Neoplasms
    • 11.2.3. Acute Myeloid Leukemia
    • 11.2.4. Acute Lymphoblastic Leukemia
  • 11.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 11.3.1. BCR-ABL1 MBCR
    • 11.3.2. JAK2
    • 11.3.3. CALR
    • 11.3.4. MPL
    • 11.3.5. PML-RARA
    • 11.3.6. NPM1
    • 11.3.7. RUNX1-RUNX1T1
    • 11.3.8. CBFB-MYH11
    • 11.3.9. BCR-ABL1 mbcr
  • 11.4. Market Value Forecast, by Technology, 2017-2031
    • 11.4.1. qPCR
    • 11.4.2. dPCR
    • 11.4.3. Next-Generation Sequencing
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. National Reference Lab/Specialty Lab
    • 11.5.2. University Hospital/Oncology Center
    • 11.5.3. Community Hospital/IDN (Regional/National
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Blood Cancer Type
    • 11.7.2. By Blood Cancer Biomarker
    • 11.7.3. By Technology
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 12.2.1. Chronic Myeloid Leukemia
      • 12.2.1.1. Polycythemia Vera
      • 12.2.1.2. Essential Thrombocythaemia
      • 12.2.1.3. Myelofibrosis
    • 12.2.2. Myeloproliferative Neoplasms
    • 12.2.3. Acute Myeloid Leukemia
    • 12.2.4. Acute Lymphoblastic Leukemia
  • 12.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 12.3.1. BCR-ABL1 MBCR
    • 12.3.2. JAK2
    • 12.3.3. CALR
    • 12.3.4. MPL
    • 12.3.5. PML-RARA
    • 12.3.6. NPM1
    • 12.3.7. RUNX1-RUNX1T1
    • 12.3.8. CBFB-MYH11
    • 12.3.9. BCR-ABL1 mbcr
  • 12.4. Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. qPCR
    • 12.4.2. dPCR
    • 12.4.3. Next-Generation Sequencing
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. National Reference Lab/Specialty Lab
    • 12.5.2. University Hospital/Oncology Center
    • 12.5.3. Community Hospital/IDN (Regional/National
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Blood Cancer Type
    • 12.7.2. By Blood Cancer Biomarker
    • 12.7.3. By Technology
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 13.2.1. Chronic Myeloid Leukemia
      • 13.2.1.1. Polycythemia Vera
      • 13.2.1.2. Essential Thrombocythaemia
      • 13.2.1.3. Myelofibrosis
    • 13.2.2. Myeloproliferative Neoplasms
    • 13.2.3. Acute Myeloid Leukemia
    • 13.2.4. Acute Lymphoblastic Leukemia
  • 13.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 13.3.1. BCR-ABL1 MBCR
    • 13.3.2. JAK2
    • 13.3.3. CALR
    • 13.3.4. MPL
    • 13.3.5. PML-RARA
    • 13.3.6. NPM1
    • 13.3.7. RUNX1-RUNX1T1
    • 13.3.8. CBFB-MYH11
    • 13.3.9. BCR-ABL1 mbcr
  • 13.4. Market Value Forecast, by Technology, 2017-2031
    • 13.4.1. qPCR
    • 13.4.2. dPCR
    • 13.4.3. Next-Generation Sequencing
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. National Reference Lab/Specialty Lab
    • 13.5.2. University Hospital/Oncology Center
    • 13.5.3. Community Hospital/IDN (Regional/National
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Blood Cancer Type
    • 13.7.2. By Blood Cancer Biomarker
    • 13.7.3. By Technology
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 14.2.1. Chronic Myeloid Leukemia
      • 14.2.1.1. Polycythemia Vera
      • 14.2.1.2. Essential Thrombocythaemia
      • 14.2.1.3. Myelofibrosis
    • 14.2.2. Myeloproliferative Neoplasms
    • 14.2.3. Acute Myeloid Leukemia
    • 14.2.4. Acute Lymphoblastic Leukemia
  • 14.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 14.3.1. BCR-ABL1 MBCR
    • 14.3.2. JAK2
    • 14.3.3. CALR
    • 14.3.4. MPL
    • 14.3.5. PML-RARA
    • 14.3.6. NPM1
    • 14.3.7. RUNX1-RUNX1T1
    • 14.3.8. CBFB-MYH11
    • 14.3.9. BCR-ABL1 mbcr
  • 14.4. Market Value Forecast, by Technology, 2017-2031
    • 14.4.1. qPCR
    • 14.4.2. dPCR
    • 14.4.3. Next-Generation Sequencing
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. National Reference Lab/Specialty Lab
    • 14.5.2. University Hospital/Oncology Center
    • 14.5.3. Community Hospital/IDN (Regional/National
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Blood Cancer Type
    • 14.7.2. By Blood Cancer Biomarker
    • 14.7.3. By Technology
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 15.2.1. Chronic Myeloid Leukemia
      • 15.2.1.1. Polycythemia Vera
      • 15.2.1.2. Essential Thrombocythaemia
      • 15.2.1.3. Myelofibrosis
    • 15.2.2. Myeloproliferative Neoplasms
    • 15.2.3. Acute Myeloid Leukemia
    • 15.2.4. Acute Lymphoblastic Leukemia
  • 15.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 15.3.1. BCR-ABL1 MBCR
    • 15.3.2. JAK2
    • 15.3.3. CALR
    • 15.3.4. MPL
    • 15.3.5. PML-RARA
    • 15.3.6. NPM1
    • 15.3.7. RUNX1-RUNX1T1
    • 15.3.8. CBFB-MYH11
    • 15.3.9. BCR-ABL1 mbcr
  • 15.4. Market Value Forecast, by Technology, 2017-2031
    • 15.4.1. qPCR
    • 15.4.2. dPCR
    • 15.4.3. Next-Generation Sequencing
    • 15.4.4. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. National Reference Lab/Specialty Lab
    • 15.5.2. University Hospital/Oncology Center
    • 15.5.3. Community Hospital/IDN (Regional/National
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Blood Cancer Type
    • 15.7.2. By Blood Cancer Biomarker
    • 15.7.3. By Technology
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Asuragen, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Bio-Rad Laboratories, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. ICON plc
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Invivoscribe, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. QIAGEN N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Thermo Fisher Scientific, Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Cepheid
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Illumina, Inc.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 02: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 03: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 04: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 08: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 09: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 10: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 13: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 14: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 18: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 19: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 20: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 23: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 24: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 28: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 29: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 30: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Type, 2022
  • Figure 03: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Biomarker, 2022
  • Figure 04: Global Onco-hematology Molecular Testing Market Value Share, by Technology, 2022
  • Figure 05: Global Onco-hematology Molecular Testing Market Value Share, by End-user, 2022
  • Figure 06: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 07: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 08: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Chronic Myeloid Leukemia , 2017-2031
  • Figure 09: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Myeloproliferative Neoplasms, 2017-2031
  • Figure 10: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 11: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 12: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by BCR-ABL1 MBCR, 2017-2031
  • Figure 13: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by JAK2, 2017-2031
  • Figure 14: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Irreversible CALR, 2017-2031
  • Figure 15: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by MPL, 2017-2031
  • Figure 16: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Others, 2017-2031
  • Figure 17: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 18: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 19: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by QPCR , 2017-2031
  • Figure 20: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by DPCR, 2017-2031
  • Figure 21: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Next-Generation Sequencing, 2017-2031
  • Figure 22: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 24: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 25: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by National Reference Lab/Specialty Lab, 2017-2031
  • Figure 26: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by University Hospital/Oncology Center, 2017-2031
  • Figure 27: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 28: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 29: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 30: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 31: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 32: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 33: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 34: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 35: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 36: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 37: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 38: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 39: North America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 40: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 41: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 42: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 43: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 45: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 46: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 47: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 48: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 49: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 50: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 51: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 52: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 53: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 54: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 55: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 56: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 57: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 58: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 59: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 60: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 61: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 62: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 63: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 65: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 66: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 67: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 68: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 69: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker, 2023-2031
  • Figure 70: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 71: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 72: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 73: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 74: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 75: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 76: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 77: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 78: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 79: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 80: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 81: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 82: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 83: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 84: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 85: Global Onco-hematology Molecular Testing Market Share Analysis, by Company (2022)